Method Change for Cancer Antigen CA19-9 and CA15-3 Assays
Tuesday, May 1, 2018
Due to low frequency of requests and consolidation of immunoassay instrumentation, we will begin to transition CA19-9 and CA15-3 assays to our reference laboratory, ARUP Laboratories, effective May 15, 2018. Laboratory Alliance of Central New York currently uses the Beckman Coulter Access DXI chemiluminescence immunoassay method for analysis of CA19-9 and the Siemens Immulite 2000 XPi chemiluminescence immunoassay method for analysis of CA15-3. ARUP uses the Roche electro-chemiluminescent immunoassay for both assays. Because ARUP uses different methodology for these tumor markers, we will report results performed by both laboratories for a period of three months so that providers can preview results from the new method for comparison and re-baseline patients. Beginning with specimens collected August 15, 2018, only results from ARUP will be reported.
No changes to order codes or specimen collection will be required at this time. The duplicate testing to be performed at ARUP will be reflexively added by Laboratory Alliance and performed at no charge to the patient. Results will be available within three to five days after the initial report from Laboratory Alliance. Interpretive comments appended to results from both Laboratory Alliance and ARUP include reference range and assays used.